We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TWG:NASDAQTop Wealth Group Holding Limited Analysis

Data as of 2026-05-06 - not real-time

$3.41

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Top Wealth Group (TWG) is trading at $3.41, just below its 20‑day SMA of $3.52 and well under the 200‑day SMA of $5.04, signaling a bearish medium‑term trend. The RSI sits at 39.8, hinting at modest oversold pressure, while the MACD remains in a bearish configuration with the histogram negative. Price is perched near the calculated support of $3.245 and faces resistance around $4.09, leaving limited upside in the near term. Volatility is elevated at roughly 29% over the past 30 days and the stock has endured an 85% max drawdown, reflecting a high‑risk profile.
Fundamentally, the company reports a -5.6% revenue decline, negative free cash flow, a debt‑to‑equity ratio of 1.5, and a trailing EPS of -$5.35, while the DCF fair value of $2.77 suggests the market price is overstated. Recent news adds mixed signals: distributorship agreements across ten markets could broaden revenue streams, yet a securities class‑action investigation introduces legal uncertainty. Given the overvalued price relative to its intrinsic estimate, weak cash generation, and heightened volatility, the outlook remains cautious.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish technicals (price below SMA20/50, MACD bearish)
  • High volatility and large recent drawdown
  • Pending securities class‑action investigation

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential revenue uplift from new distributorship agreements
  • Continued overvaluation relative to DCF fair value
  • Weak cash flow and high debt levels

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Sustained negative free cash flow and earnings
  • Elevated leverage and deteriorating balance sheet
  • Market price remains above intrinsic valuation despite limited growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth-5.60%
Profit Margin18.87%
ROE5.20%
ROA3.31%
Debt/Equity1.50
P/B Ratio0.1
Op. Cash Flow$7.8M
Free Cash Flow$-9592061

Technical Analysis

TrendBearish
RSI39.8
Support$3.24
Resistance$4.09
MA 20$3.52
MA 50$3.64
MA 200$5.04
MACDBearish
VolumeIncreasing
Fear & Greed Index90.38

Valuation

Fair Value$2.77
GradeOvervalued
TypeValue

Risk Assessment

Beta-0.18
Volatility29.37%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.